Research / Stocks / PEN PEN NYSE CIK 0001321732
Penumbra Inc · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 4 · Aug 19, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT Penumbra Inc's latest supported as-filed period reports revenue of $390.0M ; gross margin moved 194 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity RAW Current state valid · history insufficient
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.47% · OPTIONAL
Operating cash generation RAW Current state valid · history insufficient
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 11.81% · OPTIONAL
Revenue growth RAW Current state valid · history insufficient
Method Yoy · gp.fundamentals.revenue
Raw value 14.90% · CORE
Inventory pressure RAW Current state valid · history insufficient
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 113.49% · OPTIONAL
Gross margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.gross_margin
Raw value 67.93% · CORE
Operating margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.operating_margin
Raw value 10.52% · CORE
SBC intensity RAW Current state valid · history insufficient
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Governance Evidence 4 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 7 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Inventory Pressure
PEN 113.5
Peer median 72.0
Peer percentile 80th 79 valid peers · 90% coverage · +1.4 robust σ Cash Generation
PEN 11.8
Peer median -10.1
Peer percentile 79th 81 valid peers · 92% coverage · +0.6 robust σ Profitability
PEN 10.5
Peer median -6.7
Peer percentile 76th 83 valid peers · 94% coverage · +0.5 robust σ Growth
PEN 14.9
Peer median 8.8
Peer percentile 59th 76 valid peers · 86% coverage · +0.4 robust σ Sbc Intensity
PEN 3.5
Peer median 5.9
Peer percentile 41th 81 valid peers · 92% coverage · -0.3 robust σ Margin
PEN 67.9
Peer median 64.0
Peer percentile 57th 76 valid peers · 86% coverage · +0.2 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001321732-26-000037 10 governed changes · top 7 shown
01
HIGH IMPORTANCE Cash 50TH HISTORICAL PCTL · N=2
Cash & equivalents decreased 51.3% Cash & equivalents changed -51.3% from the comparable as-filed period.
Why this ranks here · [email protected] $421.8M → $205.3M Comparable → current
02
MEDIUM IMPORTANCE Margin 67TH HISTORICAL PCTL · N=3
Gross margin moved 194 bp higher Gross margin changed +194 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 65.99% → 67.93% Comparable → current
03
MEDIUM IMPORTANCE Margin 67TH HISTORICAL PCTL · N=3
Gross profit increased 18.3% Gross profit changed +18.3% from the comparable as-filed period.
Why this ranks here · [email protected] $224.0M → $264.9M Comparable → current
04
INFORMATIONAL IMPORTANCE Inventory 0TH HISTORICAL PCTL · N=4
Inventory increased 3.5% Inventory changed +3.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 3.47% -4.8% ↓ Capital expenditure $13.5M -0.9% ↓ Cash & equivalents $205.3M +0.0% ↑ Free-cash-flow proxy $32.5M -55.6% ↓ Gross margin 67.93% +0.0% ↑ Interest expense $344,000 -14.4% ↓ Interest income $1.1M +33.8% ↑ Inventory $442.7M +0.9% ↑
ACTIVE TRACE Revenue PEN · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 3.47% -4.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $13.5M -0.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $205.3M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 $32.5M -55.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 67.93% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense Q2 / 2024-06-30 $344,000 -14.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income Q3 / 2023-09-30 $1.1M +33.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $442.7M +0.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 $34.8M +6.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 $46.1M -47.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 10.52% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2023-06-30 $21.5M +7.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
4 Aug 19, 2026 Period Aug 17, 2026 0002086163-26-000008SEC ↗ 10-Q Jul 30, 2026 Period Jun 30, 2026 0001321732-26-000037SEC ↗ 8-K Jul 30, 2026 Period Jul 30, 2026 0001321732-26-000036SEC ↗ 8-K Jun 22, 2026 Period Jun 18, 2026 0001321732-26-000030SEC ↗ 4 May 21, 2026 Period May 19, 2026 0001651323-26-000002SEC ↗ 8-K May 7, 2026 Period May 6, 2026 0001321732-26-000024SEC ↗ 10-Q May 6, 2026 Period Mar 31, 2026 0001321732-26-000019SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗